- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04431752
Development of Spin-lock and FSE Acquisitions Based 3D Quantitative Biochemical Imaging for Osteoarthritis
December 6, 2023 updated by: Dr. Ho Ki Wai, Chinese University of Hong Kong
In Hong Kong, joint diseases are common health problems as identified by the Elderly Health Service under the Department of Health.
It accounts for most of the disability of the elderly in Hong Kong.
In particular, osteoarthritis (OA) is on the rise and the prevalence of OA increases with age.
Women are more likely to have OA in knee and hip joints after menopause.
A study in 2000 reported that among Hong Kong people aged 50 and above, 7 percent of men and 13 percent of women suffered from OA.
With an ageing population, it is expected that OA will become a major public health problem in Hong Kong and worldwide and the socio-economic cost of supportive care to these patients can become a major burden to Hong Kong society and many regions in the world.
Early diagnosis and prevention of OA and effective technology for treatment monitoring are very important.
At present, the management of OA is not optimal and standard quality indicators suggest that the majority of persons with the disease do not receive appropriate care.
Over half of the population affected with OA are unaware of the diagnosis.
The research team have developed a quantitative and fully automated non-contrast MRI application for early detection and monitoring of joint diseases.
The whole project was funded by the Innovation and Technology Fund (ITF) (MRP/001/18X ) started in January 2019.
This clinical trial is part of the quantitative assessment of this developed technology.
The team anticipate this innovation will address both OA diagnosis, surveillance and management.
This can potentially increase diagnostic capabilities with minimum efforts, improving patient awareness, and improved treatment monitoring of the disease state after the interventions.
Thus, the proposed technology is expected to provide betterment in the quality of life for the elderly population.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hong Kong, Hong Kong
- Recruiting
- Department of Orthopaedics & Traumatology
-
Contact:
- Ki Wai Ho, MBChB, MSc, MRCSEd, FRCSEd
- Phone Number: (852) 3505 2715
- Email: kevinho@cuhk.edu.hk
-
Principal Investigator:
- Ki Wai Ho, MBChB, MSc, MRCSEd, FRCSEd
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Healthy Volunteer and Knee Osteoarthritis Patient groups.
Description
Inclusion Criteria:
- All Patients over the age of 18
- All patients must provide their written consent
In the OA group
- Patients must be affected by primary osteoarthritis of the knee (according to ACR - American College of Rheumatology - classification)
- All patients must have pain symptoms for more than or equal to 2 months
- Radiological evidence of osteoarthritis
Exclusion Criteria:
- Contraindication to MRI
- Patient with a mental disability
- Claustrophobia
- Inflammatory arthritis
- Ongoing Pregnancy and breast-feeding
- Presence of severe diseases like terminal cancers
- Presence of metalwork in the knee
- Significant hematological diseases;
- Non-consenting patients who have not provided the written Informed Consent
- Gross lower limb deformity
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Healthy Volunteer
10 healthy volunteers to undergo radiographic examinations of the knee joint.
|
The selection of patients with different level of OA will be made using the existing Kellgren-Laurence grading systems.
The recruited patients will receive MRI exams with our enhanced sequencing.
The OA level of each patient will be determined objectively through our quantitative OA grading system on MRI, which will be compared to Kellgren-Laurence grading results to evaluate the clinical performance of the MRI.
|
Kellgren-Laurence grading I Osteoarthritis Knee
10 patients in Kellgren-Laurence grading I to undergo radiographic examinations of the knee joint.
|
The selection of patients with different level of OA will be made using the existing Kellgren-Laurence grading systems.
The recruited patients will receive MRI exams with our enhanced sequencing.
The OA level of each patient will be determined objectively through our quantitative OA grading system on MRI, which will be compared to Kellgren-Laurence grading results to evaluate the clinical performance of the MRI.
|
Kellgren-Laurence grading II Osteoarthritis Knee
10 patients in Kellgren-Laurence grading II to undergo radiographic examinations of the knee joint.
|
The selection of patients with different level of OA will be made using the existing Kellgren-Laurence grading systems.
The recruited patients will receive MRI exams with our enhanced sequencing.
The OA level of each patient will be determined objectively through our quantitative OA grading system on MRI, which will be compared to Kellgren-Laurence grading results to evaluate the clinical performance of the MRI.
|
Kellgren-Laurence grading III Osteoarthritis Knee
10 patients in Kellgren-Laurence grading III to undergo radiographic examinations of the knee joint.
|
The selection of patients with different level of OA will be made using the existing Kellgren-Laurence grading systems.
The recruited patients will receive MRI exams with our enhanced sequencing.
The OA level of each patient will be determined objectively through our quantitative OA grading system on MRI, which will be compared to Kellgren-Laurence grading results to evaluate the clinical performance of the MRI.
|
Kellgren-Laurence grading IV Osteoarthritis Knee
10 patients in Kellgren-Laurence grading IV to undergo radiographic examinations of the knee joint.
|
The selection of patients with different level of OA will be made using the existing Kellgren-Laurence grading systems.
The recruited patients will receive MRI exams with our enhanced sequencing.
The OA level of each patient will be determined objectively through our quantitative OA grading system on MRI, which will be compared to Kellgren-Laurence grading results to evaluate the clinical performance of the MRI.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Degree of cartilage wear
Time Frame: Through study completion, an average of 1 year
|
All patient will have Xrays and MRI to quantitative assess the degree of cartilage wear. The patient will be categorised based on their Kellgren-Lawrence grading. |
Through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oxford Knee Score
Time Frame: Through study completion, an average of 1 year
|
Clinical Questionnaire Assessment Tool.
Subjective patient-reported outcome measurement (Oxford Knee Score) will be performed at the time of recruitment and prior to the MRI.
Score 80-100 = Excellent, Score 70-79 = Good, Score 60-69 = Fair, Score below 60 = Poor.
|
Through study completion, an average of 1 year
|
Knee Society Function Score
Time Frame: Through study completion, an average of 1 year
|
Clinical Questionnaire Assessment Tool.
Score from 100 to -20.
The higher the score, the better the knee function outcome.
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 22, 2022
Primary Completion (Estimated)
July 1, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
May 14, 2020
First Submitted That Met QC Criteria
June 12, 2020
First Posted (Actual)
June 16, 2020
Study Record Updates
Last Update Posted (Estimated)
December 7, 2023
Last Update Submitted That Met QC Criteria
December 6, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020.115
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis, Knee
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Novartis PharmaceuticalsRecruitingSymptomatic Knee OsteoarthritisUnited States, Spain, Hungary, Argentina, Germany, Slovakia, Czechia, Belgium, Romania
-
University of BathUniversity of Oxford; 3D Metal Printing Ltd; Versus ArthritisRecruitingMedial Knee OsteoarthritisUnited Kingdom
-
Max Biocare Pty. Ltd.Completed
Clinical Trials on Magnetic Resonance Imaging Scan
-
M.D. Anderson Cancer CenterActive, not recruitingProstate Adenocarcinoma | Prostate CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Recruiting
-
University of California, San FranciscoTerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy SubjectUnited States
-
Stanford UniversityTerminatedLaryngeal Neoplasms | Head and Neck Cancers | Larynx CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedThoracic Spine NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingThymoma | Recurrent Malignant ThymomaUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Lung Small Cell CarcinomaUnited States, Canada, Korea, Republic of, Mexico
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingIntracranial NeoplasmUnited States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedMalignant Central Nervous System NeoplasmUnited States